Literature DB >> 21833451

Suboptimal anticoagulation with pre-hospital heparin in ST-elevation myocardial infarction.

Renicus S Hermanides1, Jan Paul Ottervanger, Jan-Henk E Dambrink, Menko-Jan de Boer, Jan C A Hoorntje, A T Marcel Gosselink, Harry Suryapranata, Felix Zijlstra, Arnoud W J van 't Hof.   

Abstract

This is a prospective, observational study performed in all consecutive ST-elevation myocardial infarction (STEMI) patients who had activated clotting time (ACT) measurement on arrival in the cathlab before coronary angiography. We studied the therapeutic effects of a pre-hospital fixed heparin bolus dose in consecutive patients with STEMI. A total of 1,533 patients received pre-hospital administration of aspirin, high dose clopidogrel (600 mg) and a fixed bolus dose of 5,000 IU unfractionated heparin (UFH), according to the national ambulance protocols. Some patients were also treated with glycoprotein IIb/IIIa inhibitors (GPI) in the ambulance. A therapeutic ACT range was defined according to the ESC guidelines as 200-250 seconds when patients had GPI pre-treatment and 250-350 seconds when no GPI pre-treatment. Of the 1,533 patients, 216 patients (14.1%) had an ACT within the therapeutic range, 82.3% of the patients had a too low ACT, whereas 3.5% of the patients had a too high ACT. After multivariable analysis, the only independent predictor of a too low ACT was increasing weight (odds ratio 1.02/kg, 95% confidence interval 1.01-1.03, p=0.001). Patients with a too low ACT had less often an open infarct related vessel (initial TIMI flow 2,3) as compared to patients with an ACT in range (36.5% vs. 45.9%, p=0.013). In only a minority of patients with STEMI, pre-hospital treatment with a fixed bolus dose UFH is within the therapeutic ACT range. Increased weight is an independent determinant of a too low ACT. We strongly recommend weight adjusted administration of UFH in the ambulance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833451     DOI: 10.1160/TH11-04-0257

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  2 in total

Review 1.  Anticoagulation in neurointerventions: basic pharmacology and pathophysiology, current status, practical advice.

Authors:  J Scharf; C-E Dempfle
Journal:  Clin Neuroradiol       Date:  2012-02-07       Impact factor: 3.649

2.  New guidelines on primary PCI for patients with STEMI: changing insights.

Authors:  E E van der Wall
Journal:  Neth Heart J       Date:  2016-02       Impact factor: 2.380

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.